Biocept, Inc, a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announced a preferred provider agreement with HarlePhil Ventures, Inc., a wholly owned subsidiary of The Harle Group Inc., to market and distribute Biocept's Target Selector liquid biopsy assays in the Republic of the Philippines.
All diagnostic testing services under this agreement will be performed in Biocept's San Diego-based CLIA-certified laboratory with HarlePhil Ventures, Inc. having responsibility for sales, marketing, distribution, and reimbursement of the company's liquid biopsy platform. Additional terms of the transaction were not disclosed.
"This is our first distribution agreement in Southeast Asia and marks a key milestone in our goal of expanding the distribution of our proprietary testing services into international markets," said Michael Nall, president and CEO of Biocept. "We are delighted to partner with HarlePhil Ventures to offer cancer patients in the Philippines access to our liquid biopsy platforms. We have now announced three international distribution agreements, with our liquid biopsy tests also available in Israel and Mexico, and we anticipate expanding into additional international markets in the future."
"Our new Biocept offering aligns with our corporate commitment to bring cutting-edge commercial diagnostics services to our physician customers," said Roy J. Militante, chief executive officer of The Harle Group. "Molecular tumor profiling and monitoring using a simple blood draw can provide physicians with important information when making personalized treatment decisions for their patients with cancer, without invasive surgical biopsies."